A heated takeover battle has erupted around generic-drug company Actavis Inc. as industry players seek to shore themselves up amid increasing competition and fewer new knock-off-drug opportunities.
Drug firms stalk Actavis deal
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You
Sponsored Content